3BNC117 and 10-1074 in HIV Uninfected Adults

A Phase 1 Study of the Safety and Pharmacokinetics of the Combination of 3BNC117 and 10-1074 in HIV-uninfected Adults

This is a phase 1 clinical trial to evaluate the safety and pharmacokinetics of the highly neutralizing anti-human immunodeficiency virus-1 monoclonal antibodies 3BNC117 and 10-1074, when given in combination, in human immunodeficiency virus (HIV)-uninfected individuals. This study is intended to support the development of the combination of 3BNC117 and 10-1074 mAbs for use as prophylaxis against HIV infection in healthy HIV-uninfected individuals at risk for HIV infection.

Study Overview

• Status: Completed
• Conditions: Human Immunodeficiency Virus
• Intervention / Treatment: Drug: 3BNC117; Drug: 10-1074; Drug: Placebo

Detailed Description

The study will be conducted under a placebo-controlled, double blind, randomized allocation of the study products. Study participants in each study group will be randomized to receive intravenous infusions of 3BNC117 and 10-1074 or placebo. 3BNC117 and 10-1074 will be administered at 2 dose levels (3 mg/kg and 10 mg/kg). These doses were selected based on the planned development of subcutaneous formulations for the prophylactic use of these products. The study will consist of 3 groups. Enrollment in Group 1 will begin first and participants will be enrolled at least one day apart. Eight participants will be enrolled in each group; 6 will be randomized receive the study drugs and 2 will be randomized to receive placebo. Participants in Group 1 will receive a single infusion of each antibody at 10mg/kg at Week 0. Enrollment in Group 2 will begin only after Day 28 safety data from all participants in Group 1, including ophthalmologic exams, are available. Enrollment in Group 3 will begin only after the Day 28 safety data from all participants in Group 2 is available. If > 1 grade 3 or higher adverse events deemed probably or definitely related to the study drugs occurs in a single group, the next group will not be enrolled pending safety monitoring committee (SMC) review. Participants in Groups 2 and 3 will receive 3 infusions of each antibody at Weeks 0, 8, and 16, at a dose of either 3mg/kg or 10mg/kg. The antibodies will be administered sequentially via intravenous infusion. Each antibody will be administered over 60 minutes.

Following product infusions, study participants will return for safety assessments at multiple time points. Blood samples will be collected for safety testing at weeks 1, 2, and 4 following each infusion, then at multiple time points until the end of study follow up.

Baseline pharmacokinetic (PK) assessments will be performed before the start of the first infusion. Peak PK sampling for 3BNC117 will occur following the completion of the 3BNC117 infusion prior to the start of the 10-1074 infusion. Peak PK sampling for 10-1074 will occur following the completion of the 10-1074 infusion. Additional PK assessments will occur at multiple time points during study follow up. Study participants will be followed for a total of 24 weeks following the final antibody infusion.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10065
      • The Rockefeller University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Males and females, age 18 to 65.
• Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent with low risk of HIV exposure.
• If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception (i.e. condom with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based contraceptive with condom) for the duration of the study.

Exclusion Criteria:

• Confirmed HIV-1 or HIV-2 infection.
• History of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months.
• Any clinically significant acute or chronic medical condition (such as autoimmune diseases) that in the opinion of the investigator would preclude participation.
• Within the 12 months prior to enrollment, the participant has a history of sexually transmitted infection.
• Chronic Hepatitis B or Hepatitis C infection.
• Laboratory abnormalities in the parameters listed:
• Absolute neutrophil count ≤ 2,000;
• Hemoglobin ≤ 12 gm/dL if female; ≤ 13.5 gm/dL if male;
• Platelet count ≤ 125,000;
• Alanine Aminotransferase (ALT) ≥ 1.25 x ULN; Aspartate Aminotransferase (AST) ≥ 1.25 x ULN;
• Alkaline phosphatase ≥ 1.5 x ULN
• Total bilirubin > 1.0 x ULN;
• Creatinine ≥1.1 x ULN;
• Pregnancy or lactation.
• Any vaccination within 14 days prior to infusion
• Receipt of any experimental HIV vaccine in the past.
• History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions.
• Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1; Participants will be randomized in a 3:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.	Drug: 3BNC117; Intravenous Infusion of 3BNC117; Other Names: Monoclonal Antibody 3BNC117; Drug: 10-1074; Intravenous Infusion of 10-1074; Other Names: Monoclonal Antibody 10-1074; Drug: Placebo; Intravenous Infusion of Sterile Saline (NaCl 0.9%); Other Names: Sterile Saline (NaCl 0.9%)
Experimental: Group 2; Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 3 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.	Drug: 3BNC117; Intravenous Infusion of 3BNC117; Other Names: Monoclonal Antibody 3BNC117; Drug: 10-1074; Intravenous Infusion of 10-1074; Other Names: Monoclonal Antibody 10-1074; Drug: Placebo; Intravenous Infusion of Sterile Saline (NaCl 0.9%); Other Names: Sterile Saline (NaCl 0.9%)
Experimental: Group 3; Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.	Drug: 3BNC117; Intravenous Infusion of 3BNC117; Other Names: Monoclonal Antibody 3BNC117; Drug: 10-1074; Intravenous Infusion of 10-1074; Other Names: Monoclonal Antibody 10-1074; Drug: Placebo; Intravenous Infusion of Sterile Saline (NaCl 0.9%); Other Names: Sterile Saline (NaCl 0.9%)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number of participants who experience adverse events within 1 week after the combination of 3BNC117 and 10-1074 infusion in all study groups.	Adverse events include signs, symptoms and laboratory abnormalities, in addition to local and systemic reactogenicity adverse events.	1 week following each combination of 3BNC117 and 10-1074 infusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with induced anti-3BNC117 and anti-10-1074 antibodies		8 weeks following each combination of 3BNC117 and 10-1074 infusion
Level of induced anti-3BNC117 and anti-10-1074 antibodies		8 weeks following each combination of 3BNC117 and 10-1074 infusion
The number of participants who experience adverse events that occur during study follow up after 3BNC117 and 10-1074 infusions in all study groups.	Adverse events include signs, symptoms and laboratory abnormalities.	24-40 weeks

Other Outcome Measures

Outcome Measure	Time Frame
Neutralization activity of serum from study participants against a panel of viruses as measured by the TZM.bl neutralization assay.	24-40 weeks
Elimination half-life (t1/2) of 3BNC117 and 10-1074	24-40 weeks
Clearance (CL/F) of 3BNC117 and 10-1074	24-40 weeks
Volume of distribution (Vz/F) of 3BNC117 and 10-1074	24-40 weeks
Area under the plasma concentration versus time curve (AUC) of 3BNC117 and 10-1074	24-40 weeks
Decay Curve of of 3BNC117 and 10-1074	24-40 weeks

Collaborators and Investigators

• Sponsor: Rockefeller University
• Investigators: Principal Investigator: Yehuda Cohen, MD, Rockefeller University

Publications and helpful links

General Publications

• Valente PK, Wu Y, Cohen YZ, Caskey M, Meyers K. Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention. Clin Trials. 2021 Feb;18(1):17-27. doi: 10.1177/1740774520948042. Epub 2020 Aug 24.
• Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O'Brien C, Patel R, Shimeliovich I, Lorenzi JCC, Horowitz J, Walsh SR, Lin S, Weiner JA, Tse A, Sato A, Bennett C, Mayer B, Seaton KE, Yates NL, Baden LR, deCamp AC, Ackerman ME, Seaman MS, Tomaras GD, Nussenzweig MC, Caskey M. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. PLoS One. 2019 Aug 8;14(8):e0219142. doi: 10.1371/journal.pone.0219142. eCollection 2019.

Study record dates

Study Major Dates

• Study Start (Actual): June 23, 2016
• Primary Completion (Actual): January 9, 2018
• Study Completion (Actual): January 9, 2018

Study Registration Dates

• First Submitted: June 28, 2016
• First Submitted That Met QC Criteria: July 1, 2016
• First Posted (Estimate): July 6, 2016

Study Record Updates

• Last Update Posted (Actual): April 17, 2018
• Last Update Submitted That Met QC Criteria: April 13, 2018
• Last Verified: April 1, 2018

More Information

Terms related to this study

• Keywords: HIV Prevention; 3BNC117; Broadly neutralizing antibody; 10-1074
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immunologic Deficiency Syndromes; Immune System Diseases; Slow Virus Diseases; HIV Infections; Acquired Immunodeficiency Syndrome; Physiological Effects of Drugs; Antineoplastic Agents; Immunologic Factors; Antibodies; Immunoglobulins; Antibodies, Monoclonal; Antineoplastic Agents, Immunological
• Other Study ID Numbers: YCO-0899

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO